These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 23817323

  • 1. Drug-drug interactions during antiviral therapy for chronic hepatitis C.
    Kiser JJ, Burton JR, Everson GT.
    Nat Rev Gastroenterol Hepatol; 2013 Oct; 10(10):596-606. PubMed ID: 23817323
    [Abstract] [Full Text] [Related]

  • 2. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F, Pradat P, Virlogeux V, Zoulim F.
    Dig Dis; 2015 Oct; 33(4):613-23. PubMed ID: 26159282
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
    Yau AH, Yoshida EM.
    Can J Gastroenterol Hepatol; 2014 Sep; 28(8):445-51. PubMed ID: 25229466
    [Abstract] [Full Text] [Related]

  • 4. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
    Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM, AI444040 Study Group.
    N Engl J Med; 2014 Jan 16; 370(3):211-21. PubMed ID: 24428467
    [Abstract] [Full Text] [Related]

  • 5. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.
    Clin Gastroenterol Hepatol; 2013 Aug 16; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [Abstract] [Full Text] [Related]

  • 6. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S, Solas C, Motte A, Moreau J, Borentain P, Mokhtari S, Botta-Fridlund D, Dhiver C, Portal I, Ruiz JM, Ravaux I, Bregigeon S, Poizot-Martin I, Stein A, Gérolami R, Brouqui P, Tamalet C, Colson P.
    J Med Virol; 2014 Nov 16; 86(11):1868-76. PubMed ID: 25052594
    [Abstract] [Full Text] [Related]

  • 7. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ, Lancaster JW.
    Clin Ther; 2012 Sep 16; 34(9):1857-82. PubMed ID: 22951253
    [Abstract] [Full Text] [Related]

  • 8. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Welch NM, Jensen DM.
    Liver Int; 2015 Jan 16; 35 Suppl 1():11-7. PubMed ID: 25529082
    [Abstract] [Full Text] [Related]

  • 9. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y, Bruck R, Lurei Y, Kaspa RT, Abu-Mouch S, Shouval D, Ben-Ari Z, Israeli Association for the Study of the Liver.
    Harefuah; 2012 Dec 16; 151(12):709-14, 719. PubMed ID: 23330266
    [Abstract] [Full Text] [Related]

  • 10. Emerging therapies for hepatitis C.
    Kim DY, Ahn SH, Han KH.
    Gut Liver; 2014 Sep 16; 8(5):471-9. PubMed ID: 25228970
    [Abstract] [Full Text] [Related]

  • 11. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
    Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Buti M.
    J Hepatol; 2015 Sep 16; 63(3):564-72. PubMed ID: 25895428
    [Abstract] [Full Text] [Related]

  • 12. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A, Courjon J, Anty R, Cua E, Naqvi A, Mondain V, Cottalorda J, Ollier L, Giordanengo V.
    J Clin Virol; 2016 May 16; 78():27-30. PubMed ID: 26967675
    [Abstract] [Full Text] [Related]

  • 13. Antiviral therapy of hepatitis C in 2014: do we need resistance testing?
    Schneider MD, Sarrazin C.
    Antiviral Res; 2014 May 16; 105():64-71. PubMed ID: 24583028
    [Abstract] [Full Text] [Related]

  • 14. Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.
    Langness JA, Tabano D, Wieland A, Tise S, Pratt L, Harrington LA, Lin S, Ghuschcyan V, Nair KV, Everson GT.
    Ann Hepatol; 2017 May 16; 16(3):366-374. PubMed ID: 28425406
    [Abstract] [Full Text] [Related]

  • 15. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E.
    Biochem Pharmacol; 2014 Jun 15; 89(4):441-52. PubMed ID: 24735613
    [Abstract] [Full Text] [Related]

  • 16. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.
    Shah N, Pierce T, Kowdley KV.
    Expert Opin Investig Drugs; 2013 Sep 15; 22(9):1107-21. PubMed ID: 23735127
    [Abstract] [Full Text] [Related]

  • 17. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.
    Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA.
    J Transl Int Med; 2017 Mar 15; 5(1):8-17. PubMed ID: 28680834
    [Abstract] [Full Text] [Related]

  • 18. Sofosbuvir for the treatment of hepatitis C virus.
    Asselah T.
    Expert Opin Pharmacother; 2014 Jan 15; 15(1):121-30. PubMed ID: 24289735
    [Abstract] [Full Text] [Related]

  • 19. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.
    Clin Gastroenterol Hepatol; 2013 Nov 15; 11(11):1503-10. PubMed ID: 23707354
    [Abstract] [Full Text] [Related]

  • 20. Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions.
    Khalilieh S, Feng HP, Hulskotte EG, Wenning LA, Butterton JR.
    Clin Pharmacokinet; 2015 Jun 15; 54(6):599-614. PubMed ID: 25787025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.